AUTHORS
Luca Guarnera, MD, Jackson Hensley, N/A2, Stephan Hutter, PhD3, Atsushi Marumo, MD4, Aashray Mandala, BS5, Nandini Rajaram Siva, MD6, Mark David Orland, MD, PhD7, Serhan Unlu, MD8, Carlos Bravo-Perez, MD9, Arda Durmaz, PhD10, Christopher Haddad, BS11, Charlotte Zurowski12, Zachary Brady, BS13, Karol K Gostomczyk14, Varun K. Venkatesh, N/A15, Kartik Lakhotiya, MS16, Felipe de Almeida Sartori17, Carmelo Gurnari, MD,PhD18, Lara Jehi, MD19, Valeria Visconte, PhD20, Torsten Haferlach, MD, PhD21, Jaroslaw P. Maciejewski, MD, PhD, FACP22
AFFILIATIONS
1 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
2 Cleveland Clinic, cleveland, Ohio, United States
3 MLL Munich Leukemia Laboratory, Munich, Germany
4 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
5 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
6 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
7 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
8 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
9 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
10 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
11 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
12 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
13 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
14 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
15 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
16 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
17 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
18 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
19 Cleveland Clinic, cleveland, Ohio, United States
20 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
21 MLL Munich Leukemia Laboratory, Munich, Germany
22 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
ABSTRACT
Background: Telomere maintenance is essential for preserving chromosomal integrity and sustaining hematopoietic stem cell self-renewal. Progressive telomere attrition promotes genomic instability and contributes to clonal evolution in myeloid malignancies (PMID: 40983034). Imetelstat, a telomerase inhibitor is being investigated in MPN. However, there is a lack of information on the connection between telomere content (TC) and response to Imetelstat. Besides the better response rate described in low risk MDS with SF3B1 mutations, the targeting principles allowing to maximize response rates are not established. At least theoretically, the TC or length could be a distinguishing factor for prospective responders with the possibility that either very short or the relatively longer telomeres constitute a sensitivity factor. Therefore, we investigated TC across a large cohort of patients with MPN and explored its association with genomic features, clinical characteristics, and outcomes with the aim of defining differences useful in the future to explain response to treatment.
Methods: Diagnostic samples from 393 patients with MPN underwent whole-genome sequencing (WGS). We also studied 513 controls allowing for precise age matching. Sequencing reads were aligned to the hg19/GRCh37 reference genome, and TC together with telomeric repeat composition was inferred from aligned BAM/CRAM files using TelomereHunter (TH). TH output was previously validated using quantitative telomere PCR (PMID: 40983034). Somatic variants and cytogenetic abnormalities were annotated using standardized bioinformatic pipelines. We also analyzed alternative telomere sequences. Associations between TC and clinical characteristics, genomic features, telomeric repeat patterns, and survival outcomes were evaluated using univariable and multivariable analyses.
Results and conclusions: Our cohort comprised 121 CML, 74 PV, 76 ET, 73 MF, and 49 MPN-U. Across the entire cohort, TC showed a steady inverse correlation with age (r²=0.096, p=0.051) likely due to age range of the patients affected by these diseases. By disease types, inverse association was observed in ET, PV, and MF, but not in CML or MPN-U. TC significantly differed across MPN entities (p<0.0001), with the lowest values observed in CML (median TC=392), followed by PV (412), MF (423), ET (482), and MPN-U (516). Conversely, a cohort of controls showed a significant inverse correlation with age as expected (p<0.0001, r²=0.1783).
Among recurrent cytogenetic abnormalities, patients with a normal karyotype displayed the highest TC (median=432). Among recurrent somatic mutations, SRSF2-mutated cases showed the highest TC (median=482), in line with previous observations in MDS and AML (PMID: 40983034). SRSF2-mutated cases were enriched for canonical telomeric repeat variants (TTTGGG; p<0.0001), arguing against activation of alternative lengthening of telomeres (ALT), which is typically characterized by a distinct singleton signature. No significant differences in TC were observed among the canonical Ph(-)negative MPN driver mutations (JAK2, CALR, MPL).
Multivariable analysis identified SRSF2 mutation and a diagnosis of ET or MPN-U as independent predictors of higher TC, whereas increasing age and the presence of SH2B3 mutations were independently associated with lower TC. When patients were divided into low (<10 percentile) and high TC group (>90 percentile), we observed, in the first group, an enrichment of CML diagnosis (43% vs 18%; p=0.01) and lower presence of SRSF2 mutations (15% vs 30%, p=0.02).TC was not associated with overall survival.
Our findings identify distinct telomere content profiles across MPN subtypes and genomic backgrounds, indicating that telomere biology reflects disease-specific molecular features rather than canonical driver mutations. The enrichment of higher TC and canonical telomeric repeats in SRSF2-mutated MPNs suggests distinct mechanisms of telomere maintenance in this molecular subgroup. These observations provide a biological rationale for investigating telomere-related biomarkers such as SRSF2 in future studies of telomerase-directed therapies, including imetelstat.
DISCLOSURES
Luca Guarnera, MD: No relevant conflicts of interest to declare.